Surface Antibodies and Relapse Risks After Hepatitis B Treatment - Gastroenterology and Hepatology

More Info

---

Hello! It's great to hear about your progress in managing Hepatitis B. Your situation is quite common among patients who have undergone treatment for acute hepatitis. Let's break down your questions regarding surface antibodies, the need for continued treatment, and the risks of relapse.

First, congratulations on the positive developments in your treatment! The fact that your E antigen has turned negative and that you have developed surface antibodies (anti-HBs) with a level of 861 IU/L indicates that you have achieved a functional cure for Hepatitis B. This means that the virus is no longer detectable in your blood, and your immune system has developed a response against it.

Regarding your question about the necessity of continuing antiviral medication after your health insurance coverage ends, it is generally recommended that patients who have achieved a functional cure continue to be monitored. While the presence of surface antibodies suggests a strong immune response, there is still a small risk of relapse, especially if there are underlying liver issues or if the patient has had a long history of Hepatitis B infection.
In clinical practice, the need for additional antiviral treatment after achieving a functional cure is typically assessed on a case-by-case basis. If you have no signs of liver damage and your liver function tests remain normal, you may not need to continue antiviral therapy. However, it is advisable to have regular follow-ups with your healthcare provider to monitor your liver health and antibody levels.
As for the duration of any potential consolidation therapy, if it is deemed necessary, it usually lasts for about one year following the seroconversion of the E antigen. This is to ensure that the immune system remains robust against any potential resurgence of the virus.
Regarding the risk of relapse, studies indicate that the relapse rate for patients who have achieved a functional cure is relatively low, especially if they have developed surface antibodies. However, it is important to note that patients who have been on antiviral therapy for an extended period may have a slightly higher risk of relapse if they stop treatment. The relapse rate can vary, but it is generally estimated to be around 5-30% depending on individual factors such as the duration of infection, liver health, and the presence of any co-infections or liver diseases.

In summary, while you have made significant progress in your treatment, it is crucial to maintain regular check-ups with your healthcare provider to monitor your liver health and antibody levels. If you have any concerns about your treatment plan or the risk of relapse, discussing these with your doctor will provide you with the best personalized advice.
Lastly, remember that lifestyle factors, such as maintaining a healthy diet, avoiding alcohol, and managing stress, can also play a significant role in your overall liver health. Stay proactive about your health, and best wishes for your continued recovery!